ProfileGDS5678 / 1417177_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 73% 71% 70% 71% 73% 67% 66% 70% 70% 70% 70% 70% 70% 70% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.6656473
GSM967853U87-EV human glioblastoma xenograft - Control 24.534171
GSM967854U87-EV human glioblastoma xenograft - Control 34.3951670
GSM967855U87-EV human glioblastoma xenograft - Control 44.5622771
GSM967856U87-EV human glioblastoma xenograft - Control 54.6661273
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0702367
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0124666
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.3804670
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.3828170
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.3938770
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.3897870
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.3765770
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.3964670
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.3697370